Valuation
- Market cap
- 77,680,000
- Revenue TTM
- $0
- Net income TTM
- $-69,630,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 1,027,900
- Avg volume
- 306,224
- Day's range
- $2.63 – $2.77
- Shares out
- 28,985,000
- Stochastic %K
- 38%
- Beta
- 0.95
- Analysts
- Hold
- Price target
- $2.50
Company profile
Aerovate Therapeutics, Inc., a biopharmaceutical company, engages in the treatment of pulmonary arterial hypertension in the United States. Aerovate Therapeutics, Inc., was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 617 443 2400
- Website
- https://www.aerovatetx.com
- Address
- 930 Winter Street, Suite M-500, Waltham, United States
Latest news
No headlines yet.
